Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MLLCF)
:MLLCF
Holding MLLCF?
Track your performance easily
MLLCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.59 - $10.14
Previous CloseN/A
Volume100.00
Average Volume (3M)197.00
Market Cap
$209.64M
Enterprise Value$60.27M
Total Cash (Recent Filing)$96.13M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Mar 06, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding40,363,094
10 Day Avg. Volume151
30 Day Avg. Volume197
Standard Deviation0.30
R-Squared0.01
Alpha0.00544
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.76
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue4.28
Enterprise Value/Gross Profit8.56
Enterprise Value/Ebitda-3.69
Forecast
1Y Price Target
$5.58Price Target Upside15.05% Upside
Rating ConsensusHold
Number of Analyst Covering1
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.76% Public Companies and
Individual Investors
MLLCF FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.59 and its highest was $10.14 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $209.64M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 06, 2025 which is in 43 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 26, 2024. The company reported -$0.493 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.493.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate is -0.43.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,363,094 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.493 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MLLCF
---
Company Description
Molecular Partners
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. Molecular Partners was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun and Michael Tobias Stumpp on November 23, 2004 and is headquartered in Zurich, Switzerland.
---
MLLCF Company Deck
---
MLLCF Earnings Call
Q2 2024
0:00 / 0:00
---
MLLCF Stock 12 Month Forecast
Average Price Target
$5.58
▲(15.05% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
TG Therapeutics
―
Palvella Therapeutics
―
Marker Therapeutics
―
Pfizer
―
Best Analysts Covering MLLCF
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+20.30%
reiterated a buy rating 10 months ago
Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +20.30% per trade.
---